ARULIOS

What this means for you

Not registered yet, but its 10 Jan 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

98350520

Mark type

Stylized text

Filed

10 Jan 2024

Published for opposition

27 Aug 2024

Attorney of record

Jayme M. Torelli

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of cravings for opioid substances or opiate substances; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bile acid diarrhea; Pharmaceutical preparations for the treatment of tyrosine kinase inhibitor (TKI)-induced diarrhea; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of COVID-19; Pharmaceutical preparations for the treatment of inflammatory lung injury (ILI); Pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS); Pharmaceutical preparations for the treatment of social anxiety disorder; Pharmaceutical preparations for the treatment of performance anxiety; Pharmaceutical preparations for the treatment of public speaking anxiety; Pharmaceutical preparations for the treatment of circadian rhythm disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of non-24 hour sleep-wake disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS); Pharmaceutical preparations for the treatment of major depressive disorder (MDD); Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations for the treatment of Charcot-Marie-Tooth disease; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders

Owner

• Vanda Pharmaceuticals Inc., Washington, DC, US
• Vanda Pharmaceuticals Inc., Washington, DC, US

Prosecution history

• 26 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 25 Mar 2026 — SOU EXTENSION 3 GRANTED
• 25 Mar 2026 — SOU EXTENSION 3 FILED
• 25 Mar 2026 — SOU TEAS EXTENSION RECEIVED
• 20 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 19 Sept 2025 — SOU EXTENSION 2 GRANTED
• 19 Sept 2025 — SOU EXTENSION 2 FILED
• 19 Sept 2025 — SOU TEAS EXTENSION RECEIVED
• 13 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
• 13 Mar 2025 — SOU EXTENSION 1 GRANTED
• 12 Mar 2025 — SOU EXTENSION 1 FILED
• 12 Mar 2025 — SOU TEAS EXTENSION RECEIVED
• 22 Oct 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 27 Aug 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 27 Aug 2024 — PUBLISHED FOR OPPOSITION